Citations 465

Imaging Biomarkers of Alzheimer Disease in Multiple Sclerosis

Annals of Neurology | January 23, 2020 | Volume: 87 | Issue: 4 | Pages: 556-567

10.1002/ana.25684 | PMID 31970802

ObjectiveTo investigate β‐amyloid and tau depositions using Pittsburgh compound B (PiB) positron emission tomography (PET) and AV1451 tau PET imaging in aging multiple sclerosis (MS) patients.MethodsPatients with MS (n = 16) and controls (n = 80) matched for age, sex, andAPOEε4 status from the population‐based Mayo Clinic Study of Aging who underwent PiB PET imaging were studied. Of these individuals, 12 patients with MS and 60 matching controls also underwent AV1451 tau PET. Cortical PiB and AV1451 standard uptake value ratios (SUVrs) from the entire cortex and previously determined Alzheimer disease (AD) signature regions in the same population were calculated for group comparisons and testing for associations with age.ResultsAD signature PiB SUVr (odds ratio [OR] [95% confidence interval (CI)] = 0.52 [0.27–0.98],p= 0.044), total cortical PiB SUVr (OR [95% CI] = 0.52 [0.28–0.99],p= 0.048), and the frequency of abnormal PiB SUVrs (OR [95% CI] = 0.10 [0.01–0.90],p= 0.040) were lower in MS than controls. Although AD‐signature and total cortical AV1451 SUVrs were not different between the groups, the frequency of abnormal AV1451 SUVrs was higher (OR [95% CI] = 10.65 [1.10–103.35],p= 0.041) in MS than controls. The association of AD signature PiB SUVr with age was steeper in the controls compared to patients with MS (estimate [95% CI] = −0.14 [−0.023 to −0.006],p= 0.002). Similarly, the association of total cortical PiB SUVr with age was steeper in the controls compared to patients with MS (estimate [95% CI] = −0.13 [−0.021 to −0.005],p= 0.002). There was no difference in the association of AV1451 SUVr findings with age between the MS patients and controls.InterpretationAlthough both β‐amyloid and tau are biomarkers of cognitive aging and AD, cortical β‐amyloid deposition was lower in MS than age‐matched controls, suggesting that some aspect of MS pathobiology retards the accumulation of β‐amyloid but not the accumulation of tau.ANN NEUROL 2020;87:556–567
Effect Modifiers of TDP-43-Associated Hippocampal Atrophy Rates in Patients with Alzheimer’s Disease Neuropathological Changes

Journal of Alzheimer’s Disease | January 10, 2020 | Volume: 73 | Issue: 4 | Pages: 1511-1523

10.3233/jad-191040 | PMID 31929165

Background: Transactive response DNA-binding protein of 43 kDa (TDP-43) is associated with hippocampal atrophy in Alzheimer’s disease (AD), but whether the association is modified by other factors is unknown. Objective: To evaluate whether the associations between TDP-43 and hippocampal volume and atrophy rate are affected by age, gender, apolipoprotein E ( APOE) ɛ4, Lewy bodies (LBs), amyloid-β (Aβ), or Braak neurofibrillary tangle (NFT) stage. Methods: In this longitudinal neuroimaging-clinicopathological study of 468 cases with AD neuropathological changes (Aβ-positive) that had completed antemortem head MRI, we investigated how age, gender, APOE ɛ4, presence of LBs, Aβ, TDP-43, and Braak NFT stages are associated with hippocampal volumes and rates of atrophy over time. We included field strength in the models since our cohort included 1.5T and 3T scans. We then determined whether the associations between hippocampal atrophy and TDP-43 are modified by these factors using mixed effects models. Results: Older age, female gender, APOE ɛ4, higher field strength, higher TDP-43, and Braak NFT stages were associated with smaller hippocampi. Rate of atrophy was greater with higher TDP-43 and Braak NFT stage, but lower in older patients. The association of TDP-43 with greater rate of atrophy was enhanced in APOE ɛ4 carriers ( p = 0.04). Conclusion: Neurodegenerative effects of TDP-43 seem to be independent of most factors except perhaps APOE in cases with AD neuropathological changes. TDP-43 and tau appear to behave independently of one another.
β-Amyloid PET and neuropathology in dementia with Lewy bodies

Neurology | December 20, 2019 | Volume: 94 | Issue: 3 | Pages: No page available

10.1212/wnl.0000000000008818 | PMID 31862783

Association of Longitudinal β-Amyloid Accumulation Determined by Positron Emission Tomography With Clinical and Cognitive Decline in Adults With Probable Lewy Body Dementia

JAMA Network Open | December 2, 2019 | Volume: 2 | Issue: 12 | Pages: e1916439

10.1001/jamanetworkopen.2019.16439 | PMID 31790563

Tau‐positron emission tomography correlates with neuropathology findings

Alzheimer's & Dementia | November 26, 2019 | Volume: 16 | Issue: 3 | Pages: 561-571

10.1016/j.jalz.2019.09.079 | PMID 31784374

AbstractIntroductionComparison of tau (flortaucipir) positron emission tomography (FTP‐PET) to autopsy is important to demonstrate the relationship of FTP‐PET to neuropathologic findings.MethodsAutopsies were performed on 26 participants who had antemortem FTP‐PET. FTP‐PET standardized uptake value ratios (SUVRs) were compared to autopsy diagnoses and Braak tangle stage. Quantitative tau burden was compared to regional FTP‐PET signal.ResultsParticipants with Braak stages of IV or greater had elevated FTP‐PET signal. FTP‐PET was elevated in participants with Alzheimer's disease. An FTP‐PET SUVR cut point of 1.29 was determined to be optimal. Quantitative measurements of hippocampal and temporal lobe tau burden were highly correlated to FTP‐PET signal (rho's from 0.61 to 0.70, P ≤ .02).DiscussionElevated FTP‐PET reflects Braak IV or greater neuropathology. Participants with primary age‐related tauopathy and hippocampal sclerosis did not show elevated FTP‐PET signal. Secondary neuropathologic diagnoses of Alzheimer's disease neuropathologic change can lead to borderline elevated FTP‐PET signal.
IC‐P‐099: SUBJECT FACTORS RELATED TO CSF DYNAMICS CONFOUND MEASUREMENT OF CSF BIOMARKERS IN ADNI

Alzheimer's & Dementia | October 18, 2019 | Volume: 15 | Issue: 7S_Part_2 | Pages: No page available

10.1016/j.jalz.2019.06.4942

IC‐P‐078: ALTERED CSF DYNAMICS INFLUENCE DISCREPANCIES BETWEEN CSF AND PET BIOMARKERS OF AMYLOID

Alzheimer's & Dementia | October 18, 2019 | Volume: 15 | Issue: 7S_Part_1 | Pages: No page available

10.1016/j.jalz.2019.06.4921

O4‐12‐01: TAU PET IMAGING CORRELATES WITH NEUROPATHOLOGY

Alzheimer's & Dementia | October 18, 2019 | Volume: 15 | Issue: 7S_Part_24 | Pages: No page available

10.1016/j.jalz.2019.06.4806

O3‐09‐03: RELATIONSHIP BETWEEN MIDLIFE FACTORS AND MULTIMODAL IMAGING MEASURES OF NEUROBIOLOGICAL CAPITAL: MAYO CLINIC STUDY OF AGING

Alzheimer's & Dementia | October 18, 2019 | Volume: 15 | Issue: 7S_Part_17 | Pages: No page available

10.1016/j.jalz.2019.06.4674

O2‐09‐06: TRAJECTORY OF LOBAR ATROPHY IN ASYMPTOMATIC AND SYMPTOMATIC GRN MUTATION CARRIERS: A LONGITUDINAL TBM‐SYN STUDY

Alzheimer's & Dementia | October 18, 2019 | Volume: 15 | Issue: 7S_Part_11 | Pages: No page available

10.1016/j.jalz.2019.06.4504